Adaptive Pathways and Patient AccessAn issue panel entitled Adaptive Pathways and Patient Access: Pushing Payer Boundaries or Facilitating New Payment Models? was held and moderated by Jacoline Bouvy, Scientific Adviser, National Institute for Health and Care Excellence (NICE), London, UK. Jacoline

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) opened last Monday its 19th Annual European Congress in Vienna, Austria with a plenary session entitled What Synergies Could Be Created Between Regulatory and Health Technology Assessments?The plenary discussion was moderated by

Kinesys Oncology: ESMO Congress, Copenhagen, 7-11 October 2016 Update on Lung Cancers, plus selected highlights in other tumours  Lung Cancer: http://emarketing.atalanta.uk.com/t/y-F1A2BEE45251C66C RCC, Prostate, SCLC, Gastro-Oesophageal Cancers: http://emarketing.atalanta.uk.com/t/y-0F73DC93CC39BBDA NSCLC AstraZeneca: Selumetinib misses primary endpoint. Durvalumab: 80%, 6-month survival in Phase I / II

Kinesys' CEO Gerry McGettigan will present on Regulatory & Commercial aspects of Biosimilars at the SMi Conference on 16 November 2015, Renaissance Woodbridge Hotel, Iselin, New Jersey. On 17 November, Gerry and Kinesys' Product Development Expert Graeme Deuchar will hold an interactive workshop

Kinesys delivered a Presentation labelled "Biosimilars Clinical & Regulatory Strategies Encompassing the Needs of East to West" during a visit to Suzhou, China in November 2014.  To Download the Presentation - Click Here